Lung Protocol - ADJUVANT - NON-SMALL CELL - A081105

A081105

Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC).